Tonix Pharmaceuticals Holding Corp. 8K

Tonix Pharmaceuticals announced strong second quarter 2026 revenue growth from TONMYA and other products, expanded payer coverage and sales force, and progress across its pipeline, while incurring a larger net loss and indicating its cash runway extends into early Q2 2027.

On August 10, 2026, Tonix Pharmaceuticals Holding Corp. reported its financial results for the quarter ended June 30, 2026, highlighting a sharp increase in net product revenue driven primarily by TONMYA’s U.S. commercial launch, expanded payer coverage and prescriptions, continued commercial investment and sales force expansion, and advancement of multiple clinical and preclinical pipeline programs across CNS, infectious disease, immunology, and rare disease indications, while noting a higher net loss due to increased R&D and SG&A spending and stating that existing cash resources and recent equity proceeds are expected to fund operations into early second quarter 2027.

Filing Facts

CIK

1430306

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-036740

Alert Tier

7